ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Update

ImmunityBio, Inc. (NASDAQ:IBRX) saw a large decrease in short interest in December. As of December 15th, there was short interest totalling 44,410,000 shares, a decrease of 10.8% from the November 30th total of 49,780,000 shares. Based on an average trading volume of 6,080,000 shares, the days-to-cover ratio is presently 7.3 days.

Institutional Investors Weigh In On ImmunityBio

A number of institutional investors have recently added to or reduced their stakes in IBRX. Virtu Financial LLC purchased a new position in shares of ImmunityBio in the third quarter worth $51,000. Barclays PLC increased its holdings in ImmunityBio by 127.4% in the 3rd quarter. Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after acquiring an additional 202,248 shares during the last quarter. XTX Topco Ltd increased its holdings in ImmunityBio by 309.4% in the 3rd quarter. XTX Topco Ltd now owns 92,910 shares of the company’s stock valued at $346,000 after acquiring an additional 70,215 shares during the last quarter. State Street Corp lifted its stake in ImmunityBio by 10.1% in the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares in the last quarter. Finally, HighTower Advisors LLC bought a new position in shares of ImmunityBio during the 3rd quarter valued at about $136,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Price Performance

Shares of NASDAQ:IBRX traded down $0.10 during trading on Monday, hitting $2.68. 8,005,390 shares of the company’s stock were exchanged, compared to its average volume of 5,070,578. The business’s 50-day simple moving average is $4.40 and its 200 day simple moving average is $4.60. ImmunityBio has a 52-week low of $2.50 and a 52-week high of $10.53. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -2.91 and a beta of 0.86.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on IBRX shares. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a report on Friday, December 20th. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.